Malaysian Life Sciences Capital Fund: Funding, Team & Investors

The Malaysian Life Sciences Capital Fund (MLSCF) operates as a specialized venture fund, committing early-stage investments across the life sciences sector. It targets opportunities within agriculture, industrial, and healthcare biotechnology, fostering innovation and growth in nascent companies. The fund identifies and nurtures groundbreaking technologies from foundational stages, aiming to catalyze advancements in these critical fields.

Established in late 2006, the fund emerged as a strategic initiative to bolster Malaysia's biotechnology industry. Ganesh Kishore, previously Chief Biotechnology Officer at DuPont, joined as CEO, bringing significant industry expertise. This creation reflected the insight that dedicated capital and seasoned guidance were necessary to cultivate a robust life sciences ecosystem.

MLSCF primarily supports early-stage biotechnology companies, providing financial backing and strategic insight for their research and commercialization. By investing in these ventures, the fund drives novel solutions in vital sectors. Its long-term vision is to transform Malaysia's biotechnology landscape, positioning the nation as a significant participant in global life sciences innovation.

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jun 1, 2020	Greenlight Biosciences	$100.0M Series D	Jason Dinges	Baird Capital, Maveron, OAK HC/FT, Tsvc Capital, Continental Grain Company, Cormorant Asset Management, Fall Line Capital, Lewis & Clark Agrifood, Frederic Michel, Matthew Walker, TAO Capital Partners
Apr 1, 2019	Inscripta	$20.0M Series C	—	Accel, AME Cloud Ventures, ARCH Venture Partners, Gideon YU, Hardware Club, Ligature, Morado Venture Partners, NanoDimension, Paladin Capital Group, Prefix Capital, Thomvest Ventures, Venrock, Westlake Village BioPartners, Farzad Nazem, Vishal Makhijani, Foresite Capital, Merieux Equity Partners, NanoDimension
Mar 26, 2014	LanzaTech	$60.0M Series D	—	CICC Capital, Stephen Tindall, Andrew Chung, Qiming Venture Partners, Karl Purkarthofer
Jan 24, 2012	Glori Energy	$20.0M Series C	Larry Aschebrook	Advantage Capital, Kevin Skillern, GTI Ventures, Kleiner Perkins, Oxford Bioscience Partners, The Omzest Group
Oct 25, 2011	Chromatin	$10.0M Series D	—	Justin Adams OBE, Illinois Ventures, Quantitative Investment Holdings, Unilever Ventures
May 1, 2011	Cobalt Technologies	$20.0M Series D	The Whittemore Collection	EQT Life Sciences, VantagePoint Capital Partners, Burrill & Company, Harris & Harris Group, LSP, Pinnacle Ventures, @ventures

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jun 1, 2020	Greenlight Biosciences	$100.0M Series D	Jason Dinges	Baird Capital, Maveron, OAK HC/FT, Tsvc Capital, Continental Grain Company, Cormorant Asset Management, Fall Line Capital, Lewis & Clark Agrifood, Frederic Michel, Matthew Walker, TAO Capital Partners
Apr 1, 2019	Inscripta	$20.0M Series C	—	Accel, AME Cloud Ventures, ARCH Venture Partners, Gideon YU, Hardware Club, Ligature, Morado Venture Partners, NanoDimension, Paladin Capital Group, Prefix Capital, Thomvest Ventures, Venrock, Westlake Village BioPartners, Farzad Nazem, Vishal Makhijani, Foresite Capital, Merieux Equity Partners, NanoDimension
Mar 26, 2014	LanzaTech	$60.0M Series D	—	CICC Capital, Stephen Tindall, Andrew Chung, Qiming Venture Partners, Karl Purkarthofer
Jan 24, 2012	Glori Energy	$20.0M Series C	Larry Aschebrook	Advantage Capital, Kevin Skillern, GTI Ventures, Kleiner Perkins, Oxford Bioscience Partners, The Omzest Group
Oct 25, 2011	Chromatin	$10.0M Series D	—	Justin Adams OBE, Illinois Ventures, Quantitative Investment Holdings, Unilever Ventures
May 1, 2011	Cobalt Technologies	$20.0M Series D	The Whittemore Collection	EQT Life Sciences, VantagePoint Capital Partners, Burrill & Company, Harris & Harris Group, LSP, Pinnacle Ventures, @ventures

Malaysian Life Sciences Capital Fund

Subscribe, Save or Share

About

Investment Activity

Investments Made

Financial History

Investment Activity

Investments Made